

Manuel Romero-Gómez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1674573/publications.pdf>

Version: 2024-02-01

547
papers

35,632
citations

6233

80
h-index

4101

175
g-index

602
all docs

602
docs citations

602
times ranked

28371
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
2	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». <i>Gastroenterología Y Hepatología</i> , 2023, 46, 236-247.	0.2	2
3	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	6.1	113
4	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
5	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
6	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2022, 117, 138-146.	0.2	8
7	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2022, 76, 11-24.	1.8	16
8	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
9	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
10	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	2.4	35
11	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
12	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	1.0	4
13	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	1.8	66
14	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 356-362.	0.7	6
15	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	1.9	18
16	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	1.9	11
17	Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1410-1422.	1.9	14
18	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. <i>Scientific Reports</i> , 2022, 12, 3418.	1.6	19
20	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	3.6	31
21	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. <i>Journal of Gastroenterology</i> , 2022, 57, 357-371.	2.3	8
22	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
23	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
24	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	1.7	15
25	Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2022, 117, 819-819.	0.2	0
26	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
27	EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. <i>Journal of Hepatology</i> , 2022, 77, 807-824.	1.8	124
28	Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	1
29	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	2.4	47
30	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	2.4	90
31	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	3.6	20
32	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	0.6	97
33	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
34	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
35	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. <i>Clinical and Translational Medicine</i> , 2021, 11, e275.	1.7	0
36	COVID-19 and the liver: The chicken or the egg dilemma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 555.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Looking for a new name for Non-alcoholic fatty liver disease in Spanish: Esteatosis HepÃ¡tica MetabÃ³lica (EHmet). Revista Espanola De Enfermedades Digestivas, 2021, 113, 161-163.	0.1	10
38	An Experimental DUAL Model of Advanced Liver Damage. Hepatology Communications, 2021, 5, 1051-1068.	2.0	11
39	Gutâ€™Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Seminars in Liver Disease, 2021, 41, 191-205.	1.8	10
40	Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity. International Journal of Environmental Research and Public Health, 2021, 18, 3503.	1.2	10
41	Simple nonâ€invasive scoring systems and histological scores in predicting mortality in patients with nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1754-1768.	1.4	5
42	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. American Journal of Gastroenterology, 2021, 116, 1238-1247.	0.2	12
43	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	1.9	76
44	Reply to: â€œThe predictive value of significant fibrosis for metabolic disturbances in patients with NAFLDâ€ Journal of Hepatology, 2021, 74, 971-972.	1.8	0
45	Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLrâˆ’/âˆ’ mice without attenuation of steatohepatitis. Scientific Reports, 2021, 11, 8250.	1.6	14
46	European â€NAFLD Preparedness Indexâ€™ Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	2.6	27
47	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. Journal of Personalized Medicine, 2021, 11, 475.	1.1	20
48	Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model. Journal of Clinical Medicine, 2021, 10, 2208.	1.0	7
49	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsyâ€proven nonalcoholic fatty liver disease subjects. Liver International, 2021, 41, 2076-2086.	1.9	13
50	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced Science, 2021, 8, 2004168.	5.6	10
51	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. Hepatology, 2021, 74, 133-147.	3.6	101
52	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	2.6	36
53	Management of NAFLD patients with advanced fibrosis. Liver International, 2021, 41, 95-104.	1.9	7
54	Defining comprehensive models of care for NAFLD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 717-729.	8.2	72

#	ARTICLE	IF	CITATIONS
55	Wilson's disease: Revisiting an old friend. <i>World Journal of Hepatology</i> , 2021, 13, 634-649.	0.8	28
56	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1443-1451.	1.0	1
57	EASL international recognition award recipient 2021: Prof. Dr. Nahum MÃ©endez-SÃ¡nchez. <i>Journal of Hepatology</i> , 2021, 75, 10-11.	1.8	0
58	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	1.8	72
59	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
60	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
61	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. <i>Journal of Hepatology</i> , 2021, 75, 924-934.	1.8	11
62	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
63	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	1.8	100
64	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
65	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14
66	Entwicklung und Validierung des NAFLD Cirrhosis Score (NCS) zur Separierung von fortgeschrittener Fibrose und Zirrhose. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
67	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021, 73, 103661.	2.7	31
68	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 667354.	2.2	7
69	Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. <i>World Journal of Virology</i> , 2021, 10, 301-311.	1.3	3
70	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	1.6	13
71	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 8343-8356.	1.4	1
72	Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States. <i>Medicine (United States)</i> , 2021, 100, e28165.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients. <i>Cancers</i> , 2021, 13, 6153.	1.7	13
74	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
75	Development and Validation of Hepamet Fibrosis Scoring Systemâ€“A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
76	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	3.6	66
77	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
78	Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 921-930.	1.9	5
79	Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00203.	1.3	21
80	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
81	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
82	Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 585425.	1.2	14
83	Stratification of patients in NASH clinical trials: A pitfall for trial success. <i>JHEP Reports</i> , 2020, 2, 100148.	2.6	20
84	Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 1240-1251.	2.2	59
85	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142.	2.6	53
86	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patientâ€™Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	2.0	32
87	Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians. <i>Journal of Hepatology</i> , 2020, 73, S440.	1.8	2
88	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
89	Bacterial antigen translocation and age as BMIâ€™independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
90	Minimal Hepatic Encephalopathy. <i>Clinics in Liver Disease</i> , 2020, 24, 209-218.	1.0	22

#	ARTICLE	IF	CITATIONS
91	The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries. <i>Digestive and Liver Disease</i> , 2020, 52, e33-e34.	0.4	2
92	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
93	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	1.8	59
94	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. <i>American Journal of Gastroenterology</i> , 2020, 115, 989-1002.	0.2	87
95	Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2020, 52, e40-e41.	0.4	1
96	The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. <i>Liver International</i> , 2020, 40, 102-108.	1.9	125
97	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020, 31, 605-622.e10.	7.2	68
98	Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study. <i>Digestive and Liver Disease</i> , 2020, 52, e41-e42.	0.4	0
99	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
100	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
101	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
102	Coping strategies predicting quality of life in diabetic and obese NAFLD patients. <i>European Journal of Public Health</i> , 2020, 30, .	0.1	1
103	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. <i>Medicine (United States)</i> , 2020, 99, e23506.	0.4	10
104	What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist's Perspective. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 109-112.	0.7	33
105	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
106	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.3	3
107	1449-P: The Enhanced Liver Fibrosis (ELF) Score Predicts Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). <i>Diabetes</i> , 2020, 69, .	0.3	0
108	1850-P: High Prevalence of Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): The Impact on Patient-Reported Outcomes (PROs). <i>Diabetes</i> , 2020, 69, .	0.3	0

#	ARTICLE	IF	CITATIONS
109	The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries. , 2020, 58, .		0
110	Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 396-403.	0.1	0
111	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PLoS ONE, 2020, 15, e0243590.	1.1	3
112	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. Revista Espanola De Enfermedades Digestivas, 2020, 112, 778-783.	0.1	2
113	Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. Revista Espanola De Enfermedades Digestivas, 2020, 113, 125-135.	0.1	17
114	Dietary Approach to NAFLD. , 2020, , 271-287.		1
115	Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	3.6	144
116	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clinical Gastroenterology and Hepatology, 2019, 17, 748-755.e3.	2.4	559
117	Does the Antitumor Necrosis Factor-Î± Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?. Journal of Clinical Densitometry, 2019, 22, 195-202.	0.5	13
118	Relationship Between Self-Perceived Health, Vitality, and Posttraumatic Growth in Liver Transplant Recipients. Frontiers in Psychology, 2019, 10, 1367.	1.1	5
119	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology, 2019, 70, 1521-1530.	3.6	197
120	THU-466-Epigenetic regulation of gene expression in a HCC-NASH murine model. Journal of Hepatology, 2019, 70, e364-e365.	1.8	0
121	FRI-299-Transcriptomic and epigenetic characterization of a NAFLD murine model. Journal of Hepatology, 2019, 70, e526-e527.	1.8	0
122	PS-058-The socio-economic burden of NASH in Europe and the United States: The gain study. Journal of Hepatology, 2019, 70, e35-e36.	1.8	0
123	THU-438-The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2019, 70, e350.	1.8	0
124	SAT-105-Rising economic burden following the diagnosis of compensated cirrhosis among hospitalized patients with Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in Spain. Journal of Hepatology, 2019, 70, e675.	1.8	0
125	PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS. Journal of Hepatology, 2019, 70, e17-e18.	1.8	0
126	SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients. Journal of Hepatology, 2019, 70, e663-e664.	1.8	0

#	ARTICLE	IF	CITATIONS
127	SAT-151-What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis?. Journal of Hepatology, 2019, 70, e697-e698.	1.8	0
128	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2819-2821.	2.4	24
129	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation, 2019, 103, 28-38.	0.5	28
130	551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING. Gastrointestinal Endoscopy, 2019, 89, AB95.	0.5	0
131	Water-soluble extracts from edible mushrooms (<i>Agaricus bisporus</i>) as inhibitors of hepatitis C viral replication. Food and Function, 2019, 10, 3758-3767.	2.1	12
132	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. Journal of Hepatology, 2019, 70, e16-e17.	1.8	2
133	FRI-318-Effects of fatty acids and polyphenols from extra virgin olive oil in a murine animal dietary model knockout for the LDL receptor. Journal of Hepatology, 2019, 70, e536.	1.8	0
134	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2552-2560.e10.	2.4	65
135	PS-200-The combination of HEPamet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. Journal of Hepatology, 2019, 70, e133-e134.	1.8	3
136	Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization. FASEB Journal, 2019, 33, 7578-7587.	0.2	8
137	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology, 2019, 17, 2085-2092.e1.	2.4	79
138	Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. Digestive and Liver Disease, 2019, 51, e25-e26.	0.4	0
139	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms. Scientific Reports, 2019, 9, 1439.	1.6	7
140	Hepatic encephalopathy and traffic accidents: Vigilance is needed!. Journal of Hepatology, 2019, 70, 590-592.	1.8	4
141	Use of Steatotic Grafts in Liver Transplantation: Current Status. Liver Transplantation, 2019, 25, 771-786.	1.3	22
142	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1625-1633.e1.	2.4	107
143	IDDF2019-ABS-0131-...Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
144	IDDF2019-ABS-0133-...Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	P: Genetic Fingerprint of Hepatic Encephalopathy Risk in Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, S1-S1.	0.2	0
146	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
147	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. Gastroenterología Y Hepatología (English Edition), 2019, 42, 657-676.	0.0	1
148	A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy. Obesity Surgery, 2019, 29, 983-989.	1.1	8
149	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. Journal of Hepatology, 2019, 70, 494-500.	1.8	67
150	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA real-world cohort. Journal of Viral Hepatitis, 2019, 26, 55-64.	1.0	20
151	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). Gastroenterología Y Hepatología, 2019, 42, 579-592.	0.2	25
152	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. Gastroenterología Y Hepatología, 2019, 42, 657-676.	0.2	12
153	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). Revista Espanola De Enfermedades Digestivas, 2019, 111, 264-269.	0.1	16
154	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. Revista Espanola De Enfermedades Digestivas, 2019, 111, 301-307.	0.1	2
155	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. Revista Espanola De Enfermedades Digestivas, 2019, 111, 270-274.	0.1	2
156	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Revista Espanola De Enfermedades Digestivas, 2019, 111, 862-873.	0.1	12
157	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterología Y Hepatología, 2018, 41, 328-349.	0.2	71
158	Editorial: looking for patients at risk of cirrhosis in the general population "many needles in a haystack. Alimentary Pharmacology and Therapeutics, 2018, 47, 692-694.	1.9	4
159	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology, 2018, 16, 1495-1502.	2.4	83
160	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. Journal of Hepatology, 2018, 68, 940-948.	1.8	15
161	Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience. International Journal of Infectious Diseases, 2018, 67, 114-117.	1.5	23
162	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1774341.	1.4	9

#	ARTICLE	IF	CITATIONS
163	Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice. <i>Journal of Hepatology</i> , 2018, 68, S97-S98.	1.8	3
164	Clinical Outcomes in biopsy-proven NAFLD patients from the HEPamet Spanish Registry. <i>Journal of Hepatology</i> , 2018, 68, S833.	1.8	3
165	Diagnostic accuracy of <sc>SCCA</sc> and <sc>SCCA</sc>+gM for hepatocellular carcinoma: A meta-analysis. <i>Liver International</i> , 2018, 38, 1820-1831.	1.9	18
166	New therapeutic perspectives in non-alcoholic steatohepatitis. <i>Gastroenterología Y Hepatología</i> (English Edition), 2018, 41, 128-142.	0.0	0
167	Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 128-142.	0.2	10
168	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 718-725.	1.4	34
169	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 292-294.	2.4	18
170	Natural Extracts Abolished Lipid Accumulation in Cells Harboring non-favourable PNPLA3 genotype. <i>Annals of Hepatology</i> , 2018, 17, 242-249.	0.6	10
171	Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain. <i>Annals of Hepatology</i> , 2018, 17, 864-870.	0.6	3
172	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 641-649.	0.1	3
173	Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers. <i>World Journal of Gastroenterology</i> , 2018, 24, 5223-5233.	1.4	26
174	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	1.9	70
175	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> (English Edition), 2018, 41, 328-349.	0.0	7
176	Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity. <i>Journal of Hepatology</i> , 2018, 68, S832-S833.	1.8	1
177	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018, 2, 807-820.	2.0	117
178	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	0.6	536
179	Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years. <i>Journal of Hepatology</i> , 2018, 68, S218-S219.	1.8	0
180	Genetic and functional analysis of FGF21 in NAFLD/NASH. <i>Journal of Hepatology</i> , 2018, 68, S342-S343.	1.8	1

#	ARTICLE	IF	CITATIONS
181	Genetic factors of hepatic encephalopathy on patients with cirrhosis: candidate gene study. <i>Journal of Hepatology</i> , 2018, 68, S472.	1.8	0
182	Effect of hepatitis C sustained virological response on the endothelial dysfunction and the cardiovascular risk. HepCAR study. <i>Journal of Hepatology</i> , 2018, 68, S540-S541.	1.8	1
183	Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures. <i>Journal of Hepatology</i> , 2018, 68, S743.	1.8	0
184	Pregnancy and autoimmune hepatitis: presentation and outcomes. <i>Journal of Hepatology</i> , 2018, 68, S233.	1.8	1
185	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.	1.8	3
186	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018, 69, 1335-1348.	1.8	121
187	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
188	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. <i>PLoS ONE</i> , 2018, 13, e0191805.	1.1	33
189	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 427-433.	0.1	3
190	Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 223-227.	0.1	4
191	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 152, 1449-1461.e7.	0.6	209
192	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	3.6	78
193	Detecting liver fat from viscoelasticity: How good is CAP in clinical practice? The need for universal cut-offs. <i>Journal of Hepatology</i> , 2017, 66, 886-887.	1.8	13
194	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	9.4	86
195	A pragmatic algorithm to rule out Non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound. <i>Journal of Hepatology</i> , 2017, 66, S160-S161.	1.8	1
196	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	1.9	10
197	Long-term follow-up of patients with chronic hepatitis C treated with \pm -interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 792-799.	0.8	5
198	Simeprevir in combination with sofosbuvir in treatment-naïve and experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 468-475.	1.9	30

#	ARTICLE	IF	CITATIONS
199	Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry. <i>Journal of Hepatology</i> , 2017, 66, S399.	1.8	0
200	HepCom: impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, S514-S515.	1.8	0
201	Idiosyncratic Drug-Induced Liver Injury: A 20-Year Update of the Cases Enrolled By the Spanish Dili Registry. <i>Clinical Therapeutics</i> , 2017, 39, e57.	1.1	0
202	Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy. <i>Journal of Hepatology</i> , 2017, 66, S670-S671.	1.8	0
203	Treatment of NAFLD with diet, physical activity and exercise. <i>Journal of Hepatology</i> , 2017, 67, 829-846.	1.8	838
204	Critical Flicker Frequency Predicts Progression among Stages of Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, S62.	0.4	0
205	Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6Months. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1305-1312.	1.1	40
206	TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017, 153, 1448-1449.	0.6	8
207	Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1290-1295.	0.8	37
208	High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2017, 66, S311.	1.8	0
209	Time in HE in cirrhotic patients with an acute episode (â‰¥grade 2) determines short and long-term survival. <i>Journal of Hepatology</i> , 2017, 66, S372.	1.8	0
210	Oral glutamine challenge predicts risk and defines hepatic encephalopathy types. <i>Journal of Hepatology</i> , 2017, 66, S378-S379.	1.8	0
211	Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 66, S155-S156.	1.8	0
212	Genetic determinants influencing on overt hepatic encephalopathy and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2017, 66, S144.	1.8	0
213	An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat â€œWesternâ€ diet in mice. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600549.	1.5	37
214	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 332-344.	1.9	52
215	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524
216	Lactulose reduces bacterial <sc>DNA</sc> translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , 2017, 37, 212-223.	1.9	28

#	ARTICLE	IF	CITATIONS
217	Endoscopic ultrasound-guided placement of plastic pigtail stents for the drainage of refractory malignant ascites. <i>Endoscopy International Open</i> , 2017, 05, E1096-E1099.	0.9	5
218	Evolution of the incidence of inflammatory bowel disease in Southern Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 757-760.	0.1	7
219	Hepatitis B Reactivation or Hepatitis C Exacerbation in Patients with Hematological Malignancies. <i>Annals of Hepatology</i> , 2017, 16, 179-181.	0.6	6
220	Hepatitis B and NAFLD: Lives Crossed. <i>Annals of Hepatology</i> , 2017, 16, 185-187.	0.6	14
221	A real life study of <i>Helicobacter pylori</i> eradication with bismuth quadruple therapy in naïve and previously treated patients. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 552-558.	0.1	15
222	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , 2017, 9, 697.	0.8	8
223	Reply to contribution on the topic of hypovitaminosis D in chronic hepatitis C. <i>Annals of Hepatology</i> , 2016, 15, 139-140.	0.6	1
224	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2016, 22, 10064.	1.4	28
225	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.	1.6	3
226	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1611-1618.	1.4	25
227	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , 2016, 63, 1875-1887.	3.6	50
228	Reply. <i>Hepatology</i> , 2016, 64, 2266-2267.	3.6	0
229	Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. <i>Scientific Reports</i> , 2016, 6, 31777.	1.6	81
230	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016, 64, S133.	1.8	8
231	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
232	Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 181-186.	1.8	2
233	PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial. <i>Journal of Hepatology</i> , 2016, 64, S147.	1.8	2
234	A Post-Hoc Analysis of the Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy. <i>Journal of Hepatology</i> , 2016, 64, S192.	1.8	0

#	ARTICLE	IF	CITATIONS
235	Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients with Cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, S257.	1.8	2
236	A Non-Invasive Lipidomic Test Accurately Discriminates Non-Alcoholic Steatohepatitis from Steatosis: A Blind Validation Study. <i>Journal of Hepatology</i> , 2016, 64, S478.	1.8	0
237	The FTO rs1421085 T > C Polymorphism is Associated with the Severity of Non-Alcoholic Fatty Liver. <i>Journal of Hepatology</i> , 2016, 64, S490-S491.	1.8	0
238	Impact of GWAS-Identified Common Variants on Histopathological Features of Non-Alcoholic Fatty Liver Disease Patients. <i>Journal of Hepatology</i> , 2016, 64, S495-S496.	1.8	0
239	HCV Genotype 3: Meta-Analysis with Available Treatment Options. <i>Journal of Hepatology</i> , 2016, 64, S777.	1.8	0
240	Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide from the Spanish and Latin-American DILI Registries. <i>Journal of Hepatology</i> , 2016, 64, S239-S240.	1.8	0
241	Development and Validation of a Non-Invasive Model for Predicting Fibrosis Resolution One Year after Lifestyle Intervention for Biopsy-Proven Non-Alcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, S480.	1.8	0
242	Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, S499-S500.	1.8	1
243	High Resolution Analysis for Genotypes and Subgenotypes Identification in Hepatitis C Reveals the Importance of Mixed Infections for Optimal Therapy. <i>Journal of Hepatology</i> , 2016, 64, S616-S617.	1.8	0
244	Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, 1456-1465.	0.2	163
245	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 839-845.	2.8	42
246	Remission maintained by monotherapy after biological+ immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 112-118.	1.4	10
247	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with <scp>NAFLD</scp> using the <scp>SAF</scp> score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 877-889.	1.9	70
248	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016, 17, 1587-1594.	0.6	10
249	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <i>Psychopharmacology</i> , 2016, 233, 3947-3952.	1.5	40
250	Impact of Basal Comorbidities on the Overall Benefit of DAA Therapy in Hepatitis C. <i>Journal of Hepatology</i> , 2016, 64, S777-S778.	1.8	0
251	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 1627-1632.	1.5	5
252	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	5.8	104

#	ARTICLE	IF	CITATIONS
253	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	1.6	33
254	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 779-789.	1.1	25
255	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	3.6	83
256	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	1.8	64
257	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
258	Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 283-290.	0.4	29
259	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	1.5	10
260	A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. <i>PLoS ONE</i> , 2016, 11, e0150569.	1.1	4
261	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , 2016, 22, 5285.	1.4	10
262	O042 : Weight loss intensity is strongly associated to improvement of histological parameters in patients with nonalcoholic steatohepatitis after 52 weeks of lifestyle modification. <i>Journal of Hepatology</i> , 2015, 62, S209-S210.	1.8	0
263	Metabolic risk factors affect clinical Phenotype and outcome of Hepatotoxicity (DILI). <i>Clinical Therapeutics</i> , 2015, 37, e126-e127.	1.1	0
264	P0122 : Type 2 diabetes reduces overall survival and increases the risk of hepatic decompensation in HCV-related liver cirrhosis. Results from a prospective long-term study during 8 years. <i>Journal of Hepatology</i> , 2015, 62, S346.	1.8	0
265	P0984 : Development and validation of a simple clinical prediction model to identify patients with nonalcoholic steatohepatitis resolution after 52 weeks of lifestyle modification. <i>Journal of Hepatology</i> , 2015, 62, S715-S716.	1.8	0
266	P0215 : Metformin reduces hyperammonemia in portacaval shunted rats inhibiting glutaminase activity. <i>Journal of Hepatology</i> , 2015, 62, S386-S387.	1.8	0
267	Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 829-844.	1.9	34
268	99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. <i>American Journal of Gastroenterology</i> , 2015, 110, S850-S851.	0.2	4
269	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. <i>World Journal of Hepatology</i> , 2015, 7, 1105.	0.8	31
270	Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 9163.	1.4	10

#	ARTICLE	IF	CITATIONS
271	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. PLoS ONE, 2015, 10, e0122613.	1.1	2
272	Assessing cardiovascular risk in hepatitis C: An unmet need. World Journal of Hepatology, 2015, 7, 2214.	0.8	22
273	Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. Annals of Hepatology, 2015, 14, 457-463.	0.6	14
274	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Annals of Hepatology, 2015, 14, 477-486.	0.6	1
275	Reply. Gastroenterology, 2015, 149, 1988-1989.	0.6	2
276	P0169 : Critical flicker frequency predicts survival in patients with liver cirrhosis. Journal of Hepatology, 2015, 62, S366.	1.8	0
277	Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids. Hepatology, 2015, 61, 744-747.	3.6	8
278	P0698 : Quercetin modifies lipid droplet morphology and impairs hepatitis C viral life-cycle steps from assembly to replication steps. Journal of Hepatology, 2015, 62, S584.	1.8	0
279	P0736 : Impact of physical activity on oxidative stress in patients with hepatitis C. Journal of Hepatology, 2015, 62, S600-S601.	1.8	0
280	P0862 : First real clinical practice data on sofosbuvir, simeprevir and daclatasvir with HCV-chronically infected patients in Spain: The HepatiC registry experience. Journal of Hepatology, 2015, 62, S663-S664.	1.8	0
281	P0880 : Pharmacogenomic study to predict ribavirin and protease-inhibitor-related anemia in hepatitis C. Journal of Hepatology, 2015, 62, S671-S672.	1.8	0
282	P0938 : Olive oil consumption ameliorates non-alcoholic steatohepatitis induced by hypercaloric and hyperlipidic western diets. Journal of Hepatology, 2015, 62, S696-S697.	1.8	0
283	P0969 : Role of epigenetic factors in non-alcoholic steatohepatitis development. Journal of Hepatology, 2015, 62, S709.	1.8	1
284	P1098 : Influence of metabolic risk factors in hepatotoxicity (DILI) phenotype and outcome. Journal of Hepatology, 2015, 62, S761-S762.	1.8	0
285	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Journal of Clinical Virology, 2015, 68, 56-60.	1.6	11
286	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. Liver International, 2015, 35, 2474-2482.	1.9	47
287	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015, 149, 367-378.e5.	0.6	1,592
288	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. Genes and Immunity, 2015, 16, 297-300.	2.2	10

#	ARTICLE	IF	CITATIONS
289	Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	5.8	156
290	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4
291	Non-Î»rthrotic thrombocytopenic patients with hepatitis <sc>C</sc> virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1301-1308.	1.4	5
292	Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated With Survival of Patients With Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 1483-1489.	0.6	108
293	Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 845-857.	1.0	14
294	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. <i>Journal of Clinical Microbiology</i> , 2015, 53, 219-226.	1.8	74
295	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.	1.9	13
296	Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 437-447.	1.8	196
297	Undetectable <sc>HCV</sc> â€œ<sc>RNA</sc> at treatmentâ€week 8 results in highâ€sustained virological response in <sc>HCV</sc> G1 treatmentâ€experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	1.0	9
298	Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. <i>World Journal of Gastroenterology</i> , 2015, 21, 10776.	1.4	18
299	Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. <i>World Journal of Hepatology</i> , 2015, 7, 2497.	0.8	38
300	Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 10-6.	0.1	64
301	Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. <i>Annals of Hepatology</i> , 2015, 14, 457-63.	0.6	8
302	THDP17 Decreases Ammonia Production through Glutaminase Inhibition. A New Drug for Hepatic Encephalopathy Therapy. <i>PLoS ONE</i> , 2014, 9, e109787.	1.1	13
303	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-363.	0.6	18
304	Irisin, a Link among Fatty Liver Disease, Physical Inactivity and Insulin Resistance. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23163-23178.	1.8	61
305	P834 NON-INVASIVE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S349-S350.	1.8	0
306	P833 QUERCETIN MODULATES LIPIDS DROPLETS IN Huh7 CELLS BEARING PNPLA3 GENOTYPE GG. <i>Journal of Hepatology</i> , 2014, 60, S348-S349.	1.8	2

#	ARTICLE	IF	CITATIONS
307	O150 LOSS OF GATA4 IN HEPATIC STELLATE CELLS PROMOTES LIVER FIBROSIS. Journal of Hepatology, 2014, 60, S62.	1.8	0
308	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. Gastroenterology & Hepatology, 2014, 37, 1-8.	0.2	2
309	P479 GLUTAMINASE GENE ALTERATION DETERMINES THE ABILITY TO PREDICT OVERT HEPATIC ENCEPHALOPATHY BOLTS BY CRITICAL FLICKER FREQUENCY AND ORAL GLUTAMINE CHALLENGE. Journal of Hepatology, 2014, 60, S229.	1.8	0
310	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 291-295.	1.4	36
311	Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. Journal of Hepatology, 2014, 60, 545-553.	1.8	37
312	Serum selenium levels and oxidative balance as differential markers in hepatic damage caused by alcohol. Life Sciences, 2014, 94, 158-163.	2.0	35
313	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 2014, 61, 235-241.	1.8	35
314	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. New England Journal of Medicine, 2014, 370, 1889-1898.	13.9	1,580
315	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology, 2014, 147, 109-118.e5.	0.6	248
316	ABT-450/Ombitasvir and Dasabuvir with or without Ribavirin for HCV. New England Journal of Medicine, 2014, 370, 1983-1992.	13.9	669
317	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2014, 44, 65-73.	1.7	49
318	Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens. Value in Health, 2014, 17, A532.	0.1	0
319	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under Real-Life Conditions. Value in Health, 2014, 17, A367.	0.1	0
320	Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. Journal of Viral Hepatitis, 2014, 21, 19-24.	1.0	24
321	Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in Clinical Practice. Gastroenterology, 2014, 146, 887-890.	0.6	7
322	P213 REGULATION OF THE AKT/MTOR PATHWAY BY METFORMIN IN HEPATOCELLULAR CARCINOMA DEVELOPMENT UPON HCV INFECTION. Journal of Hepatology, 2014, 60, S137.	1.8	0
323	P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH/LATIN-AMERICAN DILI REGISTRY. Journal of Hepatology, 2014, 60, S169.	1.8	0
324	Stanozolol-induced bland cholestasis. Gastroenterology & Hepatology, 2014, 37, 71-72.	0.2	10

#	ARTICLE	IF	CITATIONS
325	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014, 60, S139.	1.8	2
326	Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.	1.8	1
327	P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES. <i>Journal of Hepatology</i> , 2014, 60, S310-S311.	1.8	0
328	P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS. <i>Journal of Hepatology</i> , 2014, 60, S452-S453.	1.8	2
329	Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection. <i>Gastroenterology</i> , 2014, 147, 119-131.e3.	0.6	30
330	P673 DETECTION AND DERIVATION RATE AFTER PEER-TO-PEER TRAINING SESSIONS IN PRIMARY CARE ON THE SCREENING OF HEPATITIS B. <i>Journal of Hepatology</i> , 2014, 60, S293.	1.8	0
331	P1142 META-ANALYSIS: ROLE OF INSULIN SENSITIZERS ADDED TO PEGINTERFERON AND RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2014, 60, S463.	1.8	0
332	P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
333	Review article: <scp>HCV</scp> genotype 3 " the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	1.9	103
334	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014, 370, 1993-2001.	13.9	752
335	SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients: ACG International Award. <i>American Journal of Gastroenterology</i> , 2014, 109, S131.	0.2	1
336	Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients. <i>American Journal of Gastroenterology</i> , 2014, 109, S133-S134.	0.2	0
337	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-63.	0.6	12
338	Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 246-54.	0.1	44
339	Polycystic liver in the adult (PLA) in Spain: analysis of a structured survey analyzing the experience and attitude of gastroenterologists in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 263-75.	0.1	0
340	Role of diabetes mellitus on hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013, 28, 277-279.	1.4	30
341	Clinical management of drug" drug interactions in HCV therapy: Challenges and solutions. <i>Journal of Hepatology</i> , 2013, 58, 792-800.	1.8	100
342	893 EARLY VIROLOGICAL RESPONSE RATES IN MONOINFECTED PATIENTS WITH HCV AND COINFECTED WITH HCV/HIV, GENOTYPES 1&4 TREATED WITH PEGINTERFERON alpha 2a AND RIBAVIRIN. OPTIM STUDY. <i>Journal of Hepatology</i> , 2013, 58, S367-S368.	1.8	0

#	ARTICLE	IF	CITATIONS
343	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	1.8	35
344	62 PHASE II HCVac STUDY OF TG4040 IMMUNOTHERAPEUTIC IN COMBINATION WITH PEGIFNa2a AND RIBAVIRIN IN GENOTYPE 1 CHC TREATMENT NAÏVE PATIENTS: SVR24 FINAL RESULTS. <i>Journal of Hepatology</i> , 2013, 58, S28.	1.8	1
345	1336 NON-ALCOHOLIC STEATOHEPATITIS INCREASES THE PRODUCTION OF ANTIBODIES AGAINST OXIDIZED LDL, ATHEROSCLEROSIS AND CARDIOVASCULAR RISK. <i>Journal of Hepatology</i> , 2013, 58, S538-S539.	1.8	0
346	EUS-guided coil versus cyanoacrylate therapy for the treatment of gastric varices: a multicenter study (with videos). <i>Gastrointestinal Endoscopy</i> , 2013, 78, 711-721.	0.5	203
347	1172 FUNCTIONAL ANALYSIS OF THE DIACYLGLYCEROL ACYLTRANSFERASE ACTIVITY-1 (DGAT1) IN THE REPLICATION OF HEPATITIS C VIRUS: EFFECT OF QUERCETIN. <i>Journal of Hepatology</i> , 2013, 58, S476-S477.	1.8	0
348	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>GastroenterologÅa Y HepatologÅa</i> , 2013, 36, 555-564.	0.2	1
349	1038 ROLE OF GENE AND microRNAs EXPRESSION RELATED TO HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A HCV-INDUCED MODEL IN VITRO. EFFECT OF METFORMIN. <i>Journal of Hepatology</i> , 2013, 58, S426-S427.	1.8	0
350	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013, 58, S46.	1.8	9
351	18 DETERMINATION OF FIBROSIS STAGE AND STEATOHEPATITIS IN PATIENTS WITH NAFLD BY OPTICAL ANALYSIS OF MAGNETIC RESONANCE IMAGES COMBINED WITH ARTIFICIAL NEURAL NETWORKS (FIBROMri) Tj ETQq1 1 0.764314 rg	1.1	0
352	799 EFFICACY AND SAFETY OF TRIPLE-THERAPY WITH PEGINTERFERON-RIBAVIRIN, AND BOCEPREVIR AS COMPASSIONATE-USE IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: INTERIM-ANALYSIS AT 12 WEEKS. <i>Journal of Hepatology</i> , 2013, 58, S326-S327.	1.8	1
353	894 IL28B-BASED MODEL FOR PREDICTION OF WEEK 4 VIRAL RESPONSE IN PEGINTERFERON-alfa2a + RIBAVIRIN TREATED HEPATITIS C GENOTYPE 1&4. FINAL REPORT WEEK 4 OPTIM STUDY. <i>Journal of Hepatology</i> , 2013, 58, S368.	1.8	0
354	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 74-80.	1.9	18
355	Meta-analysis: pegylated interferon Î±2a achieves higher early virological responses than Î±2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	1.9	6
356	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. <i>Journal of Infection</i> , 2013, 67, 185-193.	1.7	25
357	PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537.	3.6	39
358	Insulin resistance, telaprevir, and virological response in hepatitis C: The debate must go on. <i>Hepatology</i> , 2013, 58, 1874-1876.	3.6	0
359	Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. <i>World Journal of Gastroenterology</i> , 2013, 19, 7327.	1.4	103
360	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatototoxicity. <i>PLoS ONE</i> , 2013, 8, e68111.	1.1	81

#	ARTICLE	IF	CITATIONS
361	Cirrhosis is less cirrhosis without virus C. <i>Annals of Hepatology</i> , 2013, 12, 341-342.	0.6	0
362	Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. <i>Annals of Hepatology</i> , 2013, 12, 420-430.	0.6	32
363	Association between vitamin D and hepatitis C virus infection: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2013, 19, 5917.	1.4	77
364	HAVCR1 Gene Haplotypes and Infection by Different Viral Hepatitis C Virus Genotypes. <i>Vaccine Journal</i> , 2012, 19, 223-227.	3.2	8
365	Insulin Resistance Impairs Viral Dynamics Independently of Ethnicity or Genotypes. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 228-234.	1.1	10
366	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 535-542.	0.8	25
367	98 OPTICAL ANALYSIS OF LIVER MAGNETIC RESONANCE IMAGES BASED ON NEURAL NETWORKS FOR THE DETERMINATION OF FIBROSIS STAGE AND DISTRIBUTION IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Journal of Hepatology</i> , 2012, 56, S42-S43.	1.8	0
368	122 HEPATITIS C VIRUS MODULATES LDL RECEPTOR (LDLR) GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS ACCORDING TO VIRAL CLEARANCE. <i>Journal of Hepatology</i> , 2012, 56, S54.	1.8	0
369	839 HEPATITIS C VIRUS MODIFIES PROTEIN AND GENE EXPRESSION OF THE INSULIN SIGNALING PATHWAY IN VIVO AND IN VITRO. <i>Journal of Hepatology</i> , 2012, 56, S327-S328.	1.8	0
370	869 HEPATITIS C VIRUS MODIFIES THE EXPRESSION OF MICRO-RNAS ASSOCIATED WITH APOPTOSIS AND METABOLIC SYNDROME IN HUH7.5 CELLS. <i>Journal of Hepatology</i> , 2012, 56, S338-S339.	1.8	1
371	908 FACTORS INVOLVED IN SUSTAINED VIRAL RESPONSE (SVR) ACHIEVEMENT IN PATIENTS WITH FAVORABLE IL28B CC GENOTYPE IN HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S353-S354.	1.8	0
372	923 INTERACTION BETWEEN RS12979860 POLYMORPHISM OF IL28B GENE WITH BASELINE PREDICTIVE FACTORS OF RESPONSE TO TREATMENT IN PATIENTS WITH HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S359-S360.	1.8	0
373	924 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIED A NOVEL SUSCEPTIBILITY LOCUS GENE PBK (RS) Tj ETQq1 1 0.784314 rgBT (M). <i>Hepatology</i> , 2012, 56, S360.	1.8	0
374	Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1705-1710.	1.4	0
375	1109 HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY. <i>Journal of Hepatology</i> , 2012, 56, S437.	1.8	0
376	1378 EFFECT OF ABCC2 HAPLOTYPES ON INDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) SUSCEPTIBILITY. <i>Journal of Hepatology</i> , 2012, 56, S541.	1.8	0
377	1154 PEGINTERFERON ALPHA-2A ACHIEVES HIGHER EARLY VIROLOGICAL RESPONSES (RVR AND CEVR) THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCT). <i>Journal of Hepatology</i> , 2012, 56, S456.	1.8	2
378	1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFERON-2A AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2012, 56, S552.	1.8	6

#	ARTICLE	IF	CITATIONS
379	Knowledge discovery of customer satisfaction and dissatisfaction using ontology-based text analysis of critical incident dialogues. , 2012, , .		2
380	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 392-398.	0.5	47
381	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 699.	0.5	2
382	Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy. <i>PLoS ONE</i> , 2012, 7, e49279.	1.1	55
383	The Hepatitis C Virus Modulates Insulin Signaling Pathway In Vitro Promoting Insulin Resistance. <i>PLoS ONE</i> , 2012, 7, e47904.	1.1	28
384	Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression. <i>Journal of Proteome Research</i> , 2012, 11, 2521-2532.	1.8	183
385	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 547-556.	1.3	31
386	Entry of hepatitis C virus into the cell: A therapeutic target. <i>World Journal of Gastroenterology</i> , 2012, 18, 4481.	1.4	9
387	Relationship between <i>H. pylori</i> and hepatitis A virus infection. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 220-221.	0.1	2
388	Invasive pulmonary aspergillosis in a young man with Crohn's disease. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2012, 33, 294-295.	0.0	0
389	1340 HEPATITIS C VIRUS INFECTION ALTERS LIPID METABOLISM DEPENDING ON THE RS12979860 POLYMORPHISM IN THE IL28B GENE. <i>Journal of Hepatology</i> , 2011, 54, S529.	1.8	1
390	Changes in Insulin Sensitivity and Body Weight During and After Peginterferon and Ribavirin Therapy for Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 469-477.	0.6	63
391	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	0.6	412
392	Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 608-611.	0.6	9
393	Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin. <i>American Journal of Gastroenterology</i> , 2011, 106, 1246-1254.	0.2	31
394	APOC3 polymorphisms and non-alcoholic fatty liver disease: Resolving some doubts and raising others. <i>Journal of Hepatology</i> , 2011, 55, 1184-1186.	1.8	6
395	4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNLF2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS. <i>Journal of Hepatology</i> , 2011, 54, S2.	1.8	40
396	155 THDP-17 INHIBITS SELECTIVELY THE K-TYPE INTESTINAL GLUTAMINASE, BUT NOT THE TYPE-L IN VITRO AND IN VIVO. <i>Journal of Hepatology</i> , 2011, 54, S67.	1.8	0

#	ARTICLE	IF	CITATIONS
397	505 IBUPROFEN-ASSOCIATED HEPATOTOXICITY: ANALYSIS OF A CASE SERIES INCLUDED IN THE SPANISH DILI REGISTRY. <i>Journal of Hepatology</i> , 2011, 54, S206.	1.8	3
398	684 EFFECTS OF CHEMICAL MOIETIES AND POLYMORPHISMS IN THE HUMAN ABC TRANSPORTER ABCB1 (P-GLYCOPROTEIN/MDR1) IN DRUG-INDUCED LIVER INJURY. <i>Journal of Hepatology</i> , 2011, 54, S275.	1.8	0
399	777 ROLE OF RAPAMYCIN AS MTOR INHIBITOR IN VITRO AND ITS USE IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S312-S313.	1.8	0
400	Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. <i>Annals of Hepatology</i> , 2011, 10, 241-243.	0.6	1
401	Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 619-625.	0.1	3
402	The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 553-558.	1.5	8
403	Meta-analysis: insulin resistance and sustained virological response in hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 297-305.	1.9	96
404	Use of HOMA-IR in hepatitis C. <i>Journal of Viral Hepatitis</i> , 2011, 18, 675-684.	1.0	35
405	Insulin resistance and sustained virological response in hepatitis C: from bench to bedside. <i>Liver International</i> , 2011, 31, 1-3.	1.9	6
406	Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. <i>Liver International</i> , 2011, 31, 443-460.	1.9	51
407	Brain biomolecules oxidation in portacaval-shunted rats. <i>Liver International</i> , 2011, 31, 964-969.	1.9	15
408	Perspectives from Spanish infectious diseases professionals on 2009 A (H1N1) influenza: the third half. <i>Clinical Microbiology and Infection</i> , 2011, 17, 845-850.	2.8	8
409	Hepatitis C Virus and Statins: Is There a Role?. <i>Current Hepatitis Reports</i> , 2011, 10, 162-167.	0.3	0
410	Endoscopic closure of a rectovaginal fistula combining N-(2-butyl-cyanoacrylate (Histoacryl) and Resolution clips. <i>Endoscopy</i> , 2011, 43, E133-E134.	1.0	8
411	Experimental models for hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 536-541.	0.1	9
412	Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients With Cirrhosis. <i>Annals of Internal Medicine</i> , 2010, 153, 281.	2.0	68
413	Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers. <i>Hepatology</i> , 2010, 51, NA-NA.	3.6	0
414	Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. <i>Hepatology</i> , 2010, 52, 33-37.	3.6	183

#	ARTICLE	IF	CITATIONS
415	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312.	3.6	97
416	Reply:. <i>Hepatology</i> , 2010, 52, 1861-1862.	3.6	1
417	Power Doppler Ultrasonography Assessment of Entheses in Spondyloarthropathies: Response to Therapy of Enthesal Abnormalities. <i>Journal of Rheumatology</i> , 2010, 37, 2110-2117.	1.0	125
418	Propranolol-induced angioedema in a patient with chronic hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1182-1184.	0.5	6
419	<i>Campylobacter fetus</i> Peritonitis and Bacteremia in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 336-337.	1.8	19
420	Insulin Resistance and Response to Antiviral Therapy in Chronic Hepatitis C: Mechanisms and Management. <i>Digestive Diseases</i> , 2010, 28, 285-293.	0.8	9
421	1138 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI): FOLLOW-UP IN A COHORT OF PATIENTS IDENTIFIED IN 24 TERTIARY CARE CENTRES IN SPAIN. <i>Journal of Hepatology</i> , 2010, 52, S440.	1.8	0
422	1175 IL28B GENETIC VARIANTS AND HEPATITIS VIRUS INFECTION BY DIFFERENT VIRAL GENOTYPES. <i>Journal of Hepatology</i> , 2010, 52, S454.	1.8	1
423	Serum Metabolic Signature of Minimal Hepatic Encephalopathy by ¹ H-Nuclear Magnetic Resonance. <i>Journal of Proteome Research</i> , 2010, 9, 5180-5187.	1.8	54
424	Pharmacotherapy of hepatic encephalopathy in cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1317-1327.	0.9	22
425	161 THDP-17 INHIBITS THE GLUTAMINASE ACTIVITY IN CACO-2 CELL CULTURES. <i>Journal of Hepatology</i> , 2010, 52, S70-S71.	1.8	0
426	503 DIFFERENTIAL PROTEIN EXPRESSION IN THE CEREBELLUM OF PORTOCAVAL-SHUNTED RATS: A DIGE/MS STUDY. <i>Journal of Hepatology</i> , 2010, 52, S203.	1.8	0
427	513 DOUBLE-BLINDED CROSSOVER TRIAL ANALYZING THE USEFULNESS OF RIFAXIMIN IN THE TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY (MHE): AN INTERIN ANALYSIS. <i>Journal of Hepatology</i> , 2010, 52, S206-S207.	1.8	3
428	519 IGF-1 REPLACEMENT THERAPY IN RATS WITH HEPATIC ENCEPHALOPATHY INDUCED BY PORTACAVAL SHUNT. <i>Journal of Hepatology</i> , 2010, 52, S208-S209.	1.8	0
429	644 GENOME-WIDE ASSOCIATION AND HIGH THROUGHPUT GENOTYPE IMPUTATION STUDIES CONFIRM A SUSCEPTIBILITY LOCUS TO HCV INFECTION ON 6P22.1â€”P21.31. <i>Journal of Hepatology</i> , 2010, 52, S252.	1.8	1
430	Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response. <i>American Journal of Gastroenterology</i> , 2010, 105, 2164-2172.	0.2	62
431	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.	1.8	5
432	Cronkhite-Canada syndrome: a new case report of this enigmatic and infrequent disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 208-15.	0.1	1

#	ARTICLE	IF	CITATIONS
433	Steatosis and insulin resistance in hepatitis C: A way out for the virus?. World Journal of Gastroenterology, 2009, 15, 5014.	1.4	60
434	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology, 2009, 49, 2001-2009.	3.6	266
435	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology, 2009, 50, 1702-1708.	3.6	136
436	Reply:. Hepatology, 2009, 50, 2055-2055.	3.6	0
437	Gut ammonia production and its modulation. Metabolic Brain Disease, 2009, 24, 147-157.	1.4	75
438	Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver International, 2009, 29, 629-635.	1.9	196
439	Corrigendum to "Analysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcome" [J Hepatol 49 (2008) 107-114]. Journal of Hepatology, 2009, 50, 636.	1.8	1
440	306 ASSOCIATION OF MANGANESE SUPEROXIDE DISMUTASE FUNCTIONAL POLYMORPHISM (SOD2 V16A) WITH IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY. Journal of Hepatology, 2009, 50, S119-S120.	1.8	0
441	312 GENOTYPE DISTRIBUTION OF THE HEPATIC CANALICULAR TRANSPORTER ABCC2 " 24C>T POLYMORPHISM IS NOT RELATED TO DRUG-INDUCED IDIOSYNCRATIC LIVER INJURY (DILI). RELEVANCE OF ETHNIC VARIANTS IN EUROPEANS. Journal of Hepatology, 2009, 50, S122.	1.8	0
442	754 POSITIONAL CLONING IN GLS GENE: A MICROSATELLITE IN THE PROMOTER REGION PREDICTS THE RISK OF HEPATIC ENCEPHALOPATHY. Journal of Hepatology, 2009, 50, S277.	1.8	1
443	891 IMPORTANCE OF HLA-DQB1*0301 AS PREDICTIVE FACTOR OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC), GENOTYPE-1, TREATED WITH PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV). Journal of Hepatology, 2009, 50, S324.	1.8	0
444	Results of a survey about specific inflammatory bowel disease units in Andalusia. Revista Espanola De Enfermedades Digestivas, 2009, 101, 187-94.	0.1	5
445	Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Revista Espanola De Enfermedades Digestivas, 2009, 101, 395-8, 399-402.	0.1	18
446	Pathogenesis and natural course of hepatic steatosis and insulin resistance in patients with hepatitis C. Current Hepatitis Reports, 2008, 7, 113-119.	0.3	0
447	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology, 2008, 47, 810-816.	3.6	51
448	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 2008, 48, 588-596.	3.6	181
449	Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Alimentary Pharmacology and Therapeutics, 2008, 27, 780-789.	1.9	150
450	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. Journal of Hepatology, 2008, 48, 721-727.	1.8	175

#	ARTICLE	IF	CITATIONS
451	Analysis of IL-10, IL-4 and TNF- β polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114.	1.8	72
452	Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon- α 2a and ribavirin. <i>Journal of Clinical Virology</i> , 2008, 41, 264-269.	1.6	16
453	290 INSULIN RESISTANCE PREDICTS RISK FOR THE DEVELOPMENT OF VARICEAL BLEEDING. <i>Journal of Hepatology</i> , 2008, 48, S116.	1.8	0
454	593 SMOKING AND HEPATITIS C: INFLUENCE ON FIBROSIS PROGRESSION AND SUSTAINED RESPONSE. <i>Journal of Hepatology</i> , 2008, 48, S221-S222.	1.8	0
455	894 COMBINED GLUTATHIONE-S-TRANSFERASE M1 AND T1 GENETIC POLYMORPHISM AND SUSCEPTIBILITY TO DEVELOP DRUG-INDUCED IDIOSYNCRATIC LIVER INJURY (DILI). <i>Journal of Hepatology</i> , 2008, 48, S335-S336.	1.8	0
456	895 THE INFLUENCE OF AGE AND GENDER IN THE BIOCHEMICAL EXPRESSION OF IDIOSYNCRATIC LIVER INJURY. <i>Journal of Hepatology</i> , 2008, 48, S336.	1.8	0
457	1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE. <i>Journal of Hepatology</i> , 2008, 48, S375.	1.8	4
458	PTPN22 C1858T Polymorphism and the Outcome of Hepatitis C Virus Infection. <i>Viral Immunology</i> , 2008, 21, 491-494.	0.6	5
459	Pneumatic perforation of the cecum during diagnostic sigmoidoscopy. <i>Endoscopy</i> , 2007, 39, E183-E183.	1.0	3
460	Critical flicker frequency: It is time to break down barriers surrounding minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2007, 47, 10-11.	1.8	23
461	[246] HAPLOTYPES TACG AND CACG FROM GLUTAMINASE GENE PROTECT AGAINST HEPATIC ENCEPHALOPATHY. <i>Journal of Hepatology</i> , 2007, 46, S100.	1.8	0
462	[638] INFLUENCE OF INSULIN RESISTANCE AND RIBAVIRIN DOSAGE IN VIRAL DYNAMICS OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 TREATED WITH PEGINTERFERON AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2007, 46, S241.	1.8	3
463	Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. <i>Digestive and Liver Disease</i> , 2007, 39, 262-266.	0.4	14
464	Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. <i>Hepatology</i> , 2007, 45, 879-885.	3.6	282
465	Treatment of chronic hepatitis C genotype 1 with peginterferon- α 2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 899-906.	1.9	13
466	Clinical trial: pharmacodynamics and pharmacokinetics of retreatment with fixed-dose induction of peginterferon- α 2a in hepatitis C virus genotype 1 true non-responder patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1131-1138.	1.9	32
467	CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. <i>World Journal of Gastroenterology</i> , 2007, 13, 2187.	1.4	4
468	93 Amoxicillin-clavulanate (AC) associated hepatotoxicity: Analysis of a single country large cohort prospectively identified. <i>Journal of Hepatology</i> , 2006, 44, S41.	1.8	0

#	ARTICLE	IF	CITATIONS
469	182 Protein oxidation in astrocyte of porto-caval shunted rats: Role of oxidative stress in hepatic encephalopathy. <i>Journal of Hepatology</i> , 2006, 44, S76.	1.8	0
470	230 Usefulness of the measurement of critical flicker frequency in the diagnosis of minimal hepatic encephalopathy (MHE). <i>Journal of Hepatology</i> , 2006, 44, S93.	1.8	2
471	548 Sustained response in chronic hepatitis C reduces the risk to develop impaired fasting glucose and/or diabetes mellitus type 2. <i>Journal of Hepatology</i> , 2006, 44, S204.	1.8	4
472	566 Pharmacokinetics and pharmacodynamics of induction doses of peginterferon alpha-2a (40KD) (PEGASYS®) and ribavirin (COPEGUSÁ®) in HCV genotype 1 patients who failed to respond to interferon/ribavirin. <i>Journal of Hepatology</i> , 2006, 44, S210-S211.	1.8	2
473	603 Insulin resistance in co-infected HCV/HIV patients: A negative factor influencing sustained response to peginterferon plus ribavirin. <i>Journal of Hepatology</i> , 2006, 44, S223-S224.	1.8	1
474	669 Chronic liver damage after an episode of idiosyncratic drug induced liver injury (DILI). <i>Journal of Hepatology</i> , 2006, 44, S247.	1.8	0
475	Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. <i>Gastroenterology</i> , 2006, 131, 451-460.	0.6	361
476	Acute hepatitis due to <i>Mycoplasma pneumoniae</i> infection without lung involvement in adult patients. <i>Journal of Hepatology</i> , 2006, 44, 827-828.	1.8	28
477	Insulin resistance and hepatitis C. <i>World Journal of Gastroenterology</i> , 2006, 12, 7075.	1.4	139
478	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 72-80.	3.6	52
479	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856.	3.6	143
480	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.	3.6	267
481	Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1236-1241.	0.5	17
482	Different approaches to therapy of esophageal granular cell tumor (Abrikossoff tumor). <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 993-994.	0.6	2
483	Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G373-G381.	1.6	34
484	Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. <i>World Journal of Gastroenterology</i> , 2006, 12, 2406.	1.4	40
485	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs. <i>World Journal of Gastroenterology</i> , 2006, 12, 5078.	1.4	14
486	Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 161-9.	0.1	9

#	ARTICLE	IF	CITATIONS
487	Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Revista Espanola De Enfermedades Digestivas, 2006, 98, 605-15.	0.1	22
488	Results of a survey in Andalusian Endoscopy Units. Revista Espanola De Enfermedades Digestivas, 2006, 98, 929-48.	0.1	5
489	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 2005, 41, 779-789.	3.6	245
490	Role of Phosphate-Activated Glutaminase in the Pathogenesis of Hepatic Encephalopathy. Metabolic Brain Disease, 2005, 20, 319-325.	1.4	37
491	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology, 2005, 129, 512-521.	0.6	847
492	HLA-C and KIR Genes in Hepatitis C Virus Infection. Human Immunology, 2005, 66, 1106-1109.	1.2	41
493	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 2005, 128, 636-641.	0.6	699
494	Insulin Resistance and Hepatitis C. Gastroenterology, 2005, 128, 2178.	0.6	0
495	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology, 2005, 129, 512-521.	0.6	595
496	Hepatitis C: are there any options for non-responders?. Revista Espanola De Enfermedades Digestivas, 2005, 97, 299-305.	0.1	0
497	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. American Journal of Gastroenterology, 2004, 99, 2150-2157.	0.2	21
498	Transient Budd-Chiari Syndrome due to Iatrogenic Subcapsular Fluid Accumulation Following Thoracocentesis. American Journal of Gastroenterology, 2004, 99, 2281-2282.	0.2	1
499	Case Report: Histologic Features of Steatohepatitis in Patients with a Clinical Diagnosis of Autoimmune Cholestasis. Digestive Diseases and Sciences, 2004, 49, 1957-1961.	1.1	4
500	Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology, 2004, 39, 939-943.	3.6	58
501	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39, 1603-1612.	3.6	134
502	Hepatotoxicity induced by clopidogrel. Journal of Hepatology, 2004, 40, 560-562.	1.8	24
503	Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. Journal of Hepatology, 2004, 41, 49-54.	1.8	96
504	SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut, 2004, 53, 446-450.	6.1	25

#	ARTICLE	IF	CITATIONS
505	508 Insulin resistance, fibrosis and genotype are predictors of sustained response rate to pegylated interferon plus ribavirin in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2004, 40, 150.	1.8	2
506	509 Sustained virological response after prolonged treatment with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: teravic-4 study. <i>Journal of Hepatology</i> , 2004, 40, 150.	1.8	8
507	Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 761-765.	0.8	6
508	Tricobezoar gástrico complicado con úlceras gástricas perforadas. <i>Gastroenterología Y Hepatología</i> , 2004, 27, 560-560.	0.2	1
509	Peritonitis bacteriana espontánea por <i>Streptococcus anginosus</i> . <i>Gastroenterología Y Hepatología</i> , 2004, 27, 151-151.	0.2	0
510	Tumor estromal de localización gástrica. <i>Gastroenterología Y Hepatología</i> , 2004, 27, 429-429.	0.2	0
511	Three-day intravenous triple therapy is not effective for the eradication of <i>Helicobacter pylori</i> infection in patients with bleeding gastro-duodenal ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 1023-1029.	1.9	3
512	Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1135-1141.	0.2	17
513	HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1621-1626.	0.2	4
514	Hla Class I B44 Is Associated With Sustained Response To Interferon + Ribavirin Therapy in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1621-1626.	0.2	26
515	Lansoprazole-Induced Hepatic Dysfunction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1731-1731.	0.9	6
516	Fatigue is associated with high circulating leptin levels in chronic hepatitis C. <i>Gut</i> , 2003, 52, 915-915.	6.1	2
517	Familial Mediterranean Fever Mimicking Fitz-Hugh-Curtis Syndrome. <i>American Journal of Gastroenterology</i> , 2003, 98, 701-701.	0.2	3
518	Serum Leptin Levels Correlate With Hepatic Steatosis in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1135-1141.	0.2	94
519	Macro-AST as cause of unknown hypertransaminasaemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 103-104.	0.8	6
520	Hepatitis aguda por montelukast. <i>Medicina Clínica</i> , 2003, 120, 239-239.	0.3	1
521	Bursitis bacteriana espontánea en un paciente con cirrosis hepática. <i>Medicina Clínica</i> , 2003, 120, 435-435.	0.3	0
522	Fatigue is associated with high circulating leptin levels in chronic hepatitis C. <i>Gut</i> , 2002, 51, 434-439.	6.1	60

#	ARTICLE	IF	CITATIONS
523	Infliximab induces remission of pyoderma gangrenosum. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 907.	0.8	32
524	Anticoagulation therapy for recent portal vein thrombosis in a patient with liver cirrhosis suffering from variceal rebleeding. <i>Gastroenterology</i> , 2002, 122, 2095.	0.6	16
525	Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2002, 37, 781-787.	1.8	66
526	Oral glutamine challenge correlates with minimal hepatic encephalopathy and predicts overt episodes. <i>Journal of Hepatology</i> , 2002, 36, 13.	1.8	0
527	Role of leptin and hepatic stellate cell (HSC) in the development of steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 126.	1.8	0
528	Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2001, 96, 2718-2723.	0.2	64
529	Hepatotoxicity induced by fosinopril. <i>Journal of Hepatology</i> , 2001, 35, 309-310.	1.8	8
530	Oral glutamine challenge in patients with subclinical hepatic encephalopathy. <i>Journal of Hepatology</i> , 2001, 34, 75.	1.8	0
531	Host and viral factors in hepatocyte steatosis detected in chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 175.	1.8	0
532	Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. <i>Digestive and Liver Disease</i> , 2001, 33, 698-702.	0.4	38
533	Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2001, 96, 2718-2723.	0.2	346
534	Pathogenesis of hyperintensity in the globus pallidus (HIGP) in cirrhotic patients. <i>Journal of Hepatology</i> , 2001, 34, 61.	1.8	0
535	Antiphospholipid Antibodies Are Related to Portal Vein Thrombosis in Patients with Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 237-240.	1.1	51
536	Acute Hepatitis After Starting Zinc Therapy in a Patient With Presymptomatic Wilson's Disease. <i>Hepatology</i> , 2000, 32, 877.	3.6	14
537	Prevalencia y significado clÃ­nico de los anticuerpos antifosfolipÃ­dicos en la hepatitis crÃ³nica por virus C. <i>Medicina ClÃ­nica</i> , 2000, 114, 367-370.	0.3	8
538	Prevalence and clinical significance of antiphospholipid antibodies (APA) in viral chronic liver disease. <i>Journal of Hepatology</i> , 2000, 32, 102.	1.8	1
539	HLA antigens in chronic hepatitis C: Relationship with interferon response and severity of liver injury. <i>Journal of Hepatology</i> , 2000, 32, 129.	1.8	95
540	Manganese level in patients with subclinical hepatic encephalopathy (SHE). <i>Journal of Hepatology</i> , 2000, 32, 150.	1.8	1

#	ARTICLE	IF	CITATIONS
541	Norfloxacin-Induced Acute Cholestatic Hepatitis in A Patient With Alcoholic Liver Cirrhosis. American Journal of Gastroenterology, 1999, 94, 2324-2325.	0.2	13
542	Pancreatic Abscess Due To Streptococcus Salivarius After Dental Manipulation. American Journal of Gastroenterology, 1999, 94, 1987-1988.	0.2	4
543	Acute cholestatic hepatitis induced by nimesulide. Liver International, 1999, 19, 164-165.	1.9	19
544	Acute Hepatitis Related to Omeprazole. American Journal of Gastroenterology, 1999, 94, 1119-1120.	0.2	21
545	Acute liver injury associated with the use of ebrotidine, a new H ₂ -receptor antagonist. Journal of Hepatology, 1999, 31, 641-646.	1.8	55
546	Pseudomembranous Colitis Induced by Diclofenac. Journal of Clinical Gastroenterology, 1998, 26, 228.	1.1	45
547	Sarcoidosis, Sclerosing Cholangitis, and Chronic Atrophic Autoimmune Gastritis. Journal of Clinical Gastroenterology, 1998, 27, 162-165.	1.1	15